Who we are
We are an interdisciplinary team leading a transformative approach to drug R&D based on the modeling of complex biological systems#drugR&D #insilicomedicine #clinicalresearchmethodology #systemsbiology #machinelearning
People and Culture
Our people are our greatest asset
We nurture a highly collaborative and holacratic environment and provide chances to grow rapidly as evidenced by our choice to give client facing and project management responsibilities early in your career.
We set the highest standards for ourselves to deliver actionable insights to our clients and ultimately improve the life of patients suffering from serious conditions.
Management
Novadiscovery welcomes two new members to its team to strengthen its combined expertise in artificial intelligence and clinical medicine
NOVADISCOVERY, a pioneer in in silico clinical trials, today announced the strengthening of its team with the nomination of its new Chief Scientific Officer, David duVerle, and the appointment of Prof. Marc Hommel as VP of Medicine.
François-Henri BOISSEL
Co-founder & Chief Executive Officer
Frederic COGNY
Co-founder & Chief Technology Officer
Dr. David DU VERLE
Chief Scientific Officer
Braintrust
Prof. Jean-Pierre BOISSEL
Co-founder & Chairman of the Scientific Advisory Board
Prof. Jean-Yves BLAY
General Director of the Centre Leon Berard
Elsy BOGLIOLI
EVP, Chief Operating Officer at Cellectis
Pascale BOISSEL
Part time CFO – Free lance advisor in Finance, Corporate Structuring, and Operations
Dr. Hervé BRAILLY
Chairman of the Supervisory Board and co-founder of Innate Pharma
Dr. Adriano HENNEY
Avicenna Alliance for Predictive Medicine ex-Secretary General
Prof. Marc HOMMEL
Vice President of Medicine of NOVADISCOVERY
Dr. Leroy E. HOOD
Head of the Institute for Systems Biology | Co-founder of Amgen
Dr. Nicholas MARKO
Neurosurgeon and Director, UC Brain Tumor Center | President, SigmaHorizon Data Strategy Consulting
Prof. Eric VIVIER
Professor of Immunology at Aix-Marseille University and the Marseille Public Hospitals | SVP, Chief Scientific Officer at Innate Pharma
Videos
François-Henri BOISSEL at Refresh 2017
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.
Prof. Jean-Pierre BOISSEL: The impact of in silico assays on drug R&D
Specify the optimal duration which helps to obtain the target effect, the dose that has to be used to maximize this effect. In other words, it’s to help us do the operations that are done today by a rather theoretical approach.
François-Henri BOISSEL at 17th Biotech in Europe Forum – Sachs Associates
François-Henri BOISSEL introducing NOVA at 17th Biotech in Europe Forum – Sachs Associates
François-Henri BOISSEL: Introduction to NOVADISCOVERY
The human body contains 10 000 potential targets. that means that we are just at the begining and there is a huge of fields to be explored with the right tools to investigate in a capital efficient maner.